Viewray Inc (NASDAQ:VRAY) CEO Scott William Drake acquired 131,260 shares of Viewray stock in a transaction dated Tuesday, August 13th. The shares were acquired at an average cost of $3.81 per share, with a total value of $500,100.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of NASDAQ:VRAY opened at $3.93 on Friday. Viewray Inc has a one year low of $2.76 and a one year high of $10.73. The company has a 50 day moving average of $8.08 and a 200-day moving average of $8.07. The company has a debt-to-equity ratio of 0.47, a current ratio of 4.28 and a quick ratio of 3.21. The stock has a market cap of $387.03 million, a price-to-earnings ratio of -4.01 and a beta of 0.79.
Viewray (NASDAQ:VRAY) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.09). Viewray had a negative return on equity of 62.98% and a negative net margin of 128.13%. The business had revenue of $30.17 million for the quarter, compared to analyst estimates of $25.92 million. During the same quarter in the prior year, the firm earned ($0.30) EPS. The firm’s quarterly revenue was up 83.5% compared to the same quarter last year. Equities research analysts anticipate that Viewray Inc will post -1.18 earnings per share for the current year.
A number of research firms have recently commented on VRAY. ValuEngine downgraded shares of Viewray from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. TheStreet cut shares of Viewray from a “c-” rating to a “d” rating in a research report on Friday, May 3rd. BidaskClub upgraded shares of Viewray from a “strong sell” rating to a “sell” rating in a research report on Thursday. Mizuho restated a “buy” rating and issued a $9.00 price objective on shares of Viewray in a research report on Sunday, August 11th. Finally, Morgan Stanley set a $5.00 price objective on shares of Viewray and gave the company a “hold” rating in a research report on Monday. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $11.75.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Featured Article: Cost of Goods Sold (COGS)
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.